Bioprocessing & Process Optimization

Sensitively detect subtle differences in CAR-T bioprocessing methods to advance decision making1

Empower decision making in bioprocess optimization by leveraging the power of true functional T cell biology

Download application highlight

Research Area

Development Stage

Optimize

Goal

Identify T cell cytokine production differences with varied bioprocessing methods

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

IsoPlexis’ systems provide the complete picture

polyfunctional cell

Finding

Found consistently more robust, polyfunctional response in modified CAR-T manufacturing protocol

follow our data

Follow Our Data

See the latest published data in Cell Therapy

More robust polyfunctional response of CD4+ or CD8+ CAR-T cell products CD19 or CD22 with the modified manufacturing method (MM) compared to the original manufacturing method (OM).

Data demonstrates that the modified CD19/CD22 bispecific CAR-T cell manufacturing method (MM), which terminated T cell activation/transduction by culture day 3, resulted in reproducible and robust CAR-T cell production, even in the relatively more sensitive patient cells.

Download application highlight
CD4 T Cells PSI

Solution

Detect Critical Differences

Significantly higher viable TNC, Fold Expansion, Viability, Final CD3% and Transduction Efficiency in products manufactured using the MM compared to OM. Comparable CD4/CD8 ratios across the two methods.

All products using the MM met product release criteria. In addition, final product dose requirements were consistently met by culture day 7 when using the MM, augmenting process efficiency.1

OM vs MM

Request a Seminar

Request a Seminar
Discover IsoLight